Zhang Financial LLC Takes Position in Boston Scientific Corporation $BSX

Zhang Financial LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,058 shares of the medical equipment provider’s stock, valued at approximately $221,000.

Other hedge funds also recently made changes to their positions in the company. Bessemer Group Inc. lifted its holdings in Boston Scientific by 14,391.8% during the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after purchasing an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares during the last quarter. Swedbank AB lifted its holdings in Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after purchasing an additional 1,505,019 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 9,990 shares of Boston Scientific stock in a transaction on Monday, October 27th. The shares were sold at an average price of $101.13, for a total value of $1,010,288.70. Following the completion of the transaction, the director owned 27,035 shares in the company, valued at approximately $2,734,049.55. The trade was a 26.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 180,204 shares of company stock worth $18,544,846. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.4%

Shares of NYSE BSX opened at $101.00 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The stock has a market capitalization of $149.66 billion, a P/E ratio of 54.01, a PEG ratio of 2.06 and a beta of 0.61. The stock’s fifty day moving average is $101.07 and its 200 day moving average is $102.22.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the business earned $0.63 earnings per share. Boston Scientific’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on BSX. Raymond James Financial lifted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Truist Financial lifted their price target on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Barclays lifted their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.